hydrazine has been researched along with Granulocytic Leukemia, Chronic in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Autore, F; Chiusolo, P; Colangelo, M; Minnella, G; Rossi, E; Sica, S; Sora', F | 1 |
| Carrà, G; Guerrasio, A; Morotti, A; Russo, I | 1 |
| Beaver, LP; Clair, PM; Deininger, MW; Eiring, AM; Hare, TO; Heaton, WL; Mason, CC; Pomicter, AD; Senina, A; Shacham, S; Than, H; Yan, D | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kadia, T; Masarova, L; Matthews, J; Naqvi, K; Ravandi, F; Sasaki, K; Shoukier, M; Verstovsek, S | 1 |
| Chen, B; Ge, X; Lu, Y; Shen, P; Sun, L; Wang, J; Wang, Y; Yang, N; Zuo, S | 1 |
| Apperley, J; Caligiuri, MA; Eisfeld, AK; Ellis, JJ; Ferenchak, G; Gabrail, NY; Garzon, R; Goldman, JM; Harb, JG; Hokland, P; Kauffman, MG; Landesman, Y; Marcucci, G; Milojkovic, D; Neviani, P; Oaks, JJ; Perrotti, D; Reid, A; Roy, DC; Santhanam, R; Shacham, S; Smith, CL; Walker, CJ | 1 |
| Abraham, SA; Holyoake, TL | 1 |
| Dong, C; Huang, X; Ren, J; Ruan, L; Shao, C; Su, D; Wang, J | 1 |
| Bonneau, K; Bowler, AD; Chenchik, A; Deininger, MW; Eiring, AM; Gantz, KC; Heaton, WL; Iovino, AJ; Kauffman, M; Khorashad, JS; Kraft, IL; Mason, CC; O'Hare, T; Pomicter, AD; Redwine, HM; Reynolds, KR; Shacham, S; Tantravahi, SK; Ullman, KS; Yu, F; Zabriskie, MS | 1 |
| Hattori, H; Karasuno, T; Kuwayama, M; Nishiura, N; Takamori, H | 1 |
| Almasirad, A; Amanzadeh, A; Atyabi, SM; Mousavi, E; Salimi, M; Samiee-Sadr, S; Tavakolfar, S; Yaghamii, P | 1 |
| FUJIKAWA, K; INAI, S; MASAOKA, T; NAGAKI, K; TAKAHASHI, H | 1 |
1 review(s) available for hydrazine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Nuclear-cytoplasmic Shuttling in Chronic Myeloid Leukemia: Implications in Leukemia Maintenance and Therapy.
Topics: Apoptosis; Cell Nucleus; Cytoplasm; Cytosol; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Export Signals; Nuclear Localization Signals; Receptors, Cytoplasmic and Nuclear; Triazoles | 2019 |
11 other study(ies) available for hydrazine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
Topics: Animals; Benzoates; Cell Lineage; Coculture Techniques; Gene Expression Regulation, Leukemic; Humans; Hydrazines; Janus Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice, Nude; Mitogen-Activated Protein Kinases; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; STAT Transcription Factors; Thrombopoiesis; Umbilical Cord; Xenograft Model Antitumor Assays | 2021 |
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Topics: Adult; Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Proliferation; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drug Evaluation, Preclinical; Exportin 1 Protein; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Histone Chaperones; Humans; Hydrazines; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Transport; Receptors, Cytoplasmic and Nuclear; Ribonucleoproteins; Transcription Factors; Triazoles | 2013 |
Redirecting traffic using the XPO1 police.
Topics: Animals; Antineoplastic Agents; Exportin 1 Protein; Gene Expression Regulation, Leukemic; Humans; Hydrazines; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Cytoplasmic and Nuclear; Triazoles | 2013 |
A sensitive and microscale method for drug screening combining affinity probes and single molecule fluorescence correlation spectroscopy.
Topics: Antineoplastic Agents; Dasatinib; Drug Screening Assays, Antitumor; Fluorescent Dyes; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Spectrometry, Fluorescence; Thiazoles | 2015 |
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Topics: Active Transport, Cell Nucleus; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exportin 1 Protein; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Gene Library; Humans; Hydrazines; Imatinib Mesylate; K562 Cells; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; ran GTP-Binding Protein; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Signal Transduction; Triazoles; Tumor Stem Cell Assay | 2015 |
[Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
Topics: Aged; Benzoates; Biopsy; Bone Marrow; Fatal Outcome; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2014 |
In Vitro Anticancer Effects of Two New Potent Hydrazide Compounds on Leukemic Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Hydrazines; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Structure-Activity Relationship | 2016 |
DEFICIENCY OF THE HYDRAZINE SENSITIVE COMPONENT OF COMPLEMENT IN A PATIENT WITH CHRONIC MYELOGENOUS LEUKEMIA.
Topics: Animals; Blood Protein Electrophoresis; Busulfan; Complement System Proteins; Erythrocytes; Guinea Pigs; Hydrazines; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukocyte Count; Mercaptopurine; Prednisolone; Sheep | 1963 |